TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27225018

Group type: EXPERIMENTAL
Intervention: Stress cardiac magnetic resonance imaging (CMRI)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Stress myocardial perfusion scintigraphy (MPS)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: CCTA followed by invasive coronary angiography (ICA) with fractional flow reserve (FFR) measurements
Number of subjects: 2000
Study: 24809437

Group type: EXPERIMENTAL
Intervention: Individualized Mediterranean-style diet (G1: 70% breakfast, morning snack, lunch and 30% afternoon snack and dinner)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Individualized Mediterranean-style diet (G2: 55% breakfast, morning snack, lunch and 45% afternoon snack and dinner)
Number of subjects: 42
Study: 21899404

Group type: EXPERIMENTAL
Intervention: Descriptive norm messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appearance messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Descriptive norm messages (university students)
Number of subjects: 0
Study: 20551849

Group type: EXPERIMENTAL
Intervention: Calcium/vitamin D supplementation (1,000 mg of elemental calcium daily plus 400 IU of vitamin D3 daily)
Number of subjects: 754

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Calcium/vitamin D supplementation
Number of subjects: 754
Study: 18931554

Group type: EXPERIMENTAL
Intervention: Milnacipran (100 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Paroxetine (40 mg/day)
Number of subjects: 24
Study: 16188206

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (4.5 g.d(‐1))
Number of subjects: 175

Group type: COMPARATOR
Intervention: Olive oil (OO) supplementation
Number of subjects: 175

Group type: COMPARATOR
Intervention: Reference group (high habitual fish intake)
Number of subjects: 175
Study: 12651679

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.15% plus 0.5 microg/mL of sufentanil
Number of subjects: 130

Group type: COMPARATOR
Intervention: Ropivacaine 0.10% plus 0.5 microg/mL of sufentanil
Number of subjects: 130
Study: 10765964

Group type: EXPERIMENTAL
Intervention: Xylitol (n = 106); mothers chewed xylitol‐sweetened gum (65% w/w) at least 2 or 3 times a day, starting three months after delivery.
Number of subjects: 169

Group type: COMPARATOR
Intervention: Chlorhexidine (n = 30); varnish treatments at 6, 12, and 18 months after delivery.
Number of subjects: 169

Group type: COMPARATOR
Intervention: Fluoride (n = 33); varnish treatments at 6, 12, and 18 months after delivery.
Number of subjects: 169
Study: 8807372

Group type: EXPERIMENTAL
Intervention: Primary nursing in experimental units (after t1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no changes until t2)
Number of subjects: 0
Study: 1578942

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy with additional allogeneic bone marrow transplantation
Number of subjects: 156

Group type: COMPARATOR
Intervention: Autologous transplant using unpurged marrow
Number of subjects: 156

Group type: COMPARATOR
Intervention: Stopping therapy
Number of subjects: 156
Study: 3948357

Group type: EXPERIMENTAL
Intervention: Propranolol 180 or 240 mg daily
Number of subjects: 3837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study: 31892636

Group type: EXPERIMENTAL
Intervention: IV thrombolysis (alteplase 0.9 mg/kg)
Number of subjects: 859
Study: 29843670

Group type: EXPERIMENTAL
Intervention: Healthy Change intervention (four-session group obesity prevention education)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (four-session personal and food hygiene education)
Number of subjects: 360
Study: 27881914

Group type: EXPERIMENTAL
Intervention: Cocoa intake once daily (17 g, except Sundays) for 12 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cocoa intake twice daily every other day (17 g) for 12 weeks
Number of subjects: 26
Study: 23425082

Group type: EXPERIMENTAL
Intervention: Lactulose for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 60
Study: 21496065

Group type: EXPERIMENTAL
Intervention: Warfarin 25 mg co-administered with fesoterodine 8 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Warfarin 25 mg alone
Number of subjects: 14
Study: 19059539

Group type: EXPERIMENTAL
Intervention: WALK
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: RAISIN
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: RAISIN + WALK
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: RAISIN, WALK, RAISIN + WALK
Number of subjects: 34
Study: 17196454

Group type: EXPERIMENTAL
Intervention: Ranolazine (extended-release formulation in MARISA, CARISA, ERICA; immediate release in RAN080)
Number of subjects: 1737

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 1737
Study: 15071489

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine monotherapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11181777

Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Etoposide plus cisplatin plus cyclophosphamide plus 4'-epidoxorubicin (PCDE)
Number of subjects: 226
Study: 9751354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Combination
Number of subjects: 1229
Study: 8313800

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and levamisole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined modality treatment with radiotherapy and chemotherapy
Number of subjects: 0
Study: 3354256

Group type: EXPERIMENTAL
Intervention: Purified inactivated rabies vaccine (PVRV), 0.5 ml, administered on days 0, 7, and 21 (Group IA)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Purified inactivated rabies vaccine (PVRV), 0.5 ml, administered on days 0, 28, and 56 (Group IB)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Purified inactivated rabies vaccine (PVRV), 0.5 ml, administered on days 0, 3, 7, 14, 28, and 90 (Group II)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Purified inactivated rabies vaccine (PVRV), 0.5 ml, single booster for previously immunized individuals (Group III)
Number of subjects: 82
Study: 31221722

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BoNT) treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Open-label phase with BoNT treatment
Number of subjects: 48
Study: 28600025

Group type: EXPERIMENTAL
Intervention: LIVE© platform for chronic disease self-management
Number of subjects: 0
Study: 24036971

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser application after SRP (Group 3)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nd:YAG laser application (Group 1)
Number of subjects: 39

Group type: COMPARATOR
Intervention: SRP alone (Group 2)
Number of subjects: 39
Study: 23219541

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation
Number of subjects: 50
Study: 21774743

Group type: EXPERIMENTAL
Intervention: 5% lidocaine medicated plaster
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 18560537

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (0.5 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (2 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (0.5 mg and 2 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 22333546

Group type: EXPERIMENTAL
Intervention: 3DCRT plus TACE
Number of subjects: 145

Group type: COMPARATOR
Intervention: Surgical intervention
Number of subjects: 145
Study: 15953905

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid 500/125 mg 3 times a day for 4 days
Number of subjects: 490

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study: 12006119

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 165

Group type: COMPARATOR
Intervention: Needle insertion control
Number of subjects: 165

Group type: COMPARATOR
Intervention: No-needle relaxation control
Number of subjects: 165
Study: 9801110

Group type: EXPERIMENTAL
Intervention: Topical application of 0.05% PGE1 in liposomal formulations
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 8746051

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Endoscopic banding ligation
Number of subjects: 10
Study: 2784684

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 20
Study: 683118

Group type: EXPERIMENTAL
Intervention: Fe++ sulfate in a weak gelatine capsule (A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Preparation B (commercial preparation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Preparation C (commercial preparation)
Number of subjects: 12
Study: 30380357

Group type: EXPERIMENTAL
Intervention: Fiber-multivitamin combination product (treatment group, n=20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (placebo group, n=21)
Number of subjects: 41
Study: 29044466

Group type: EXPERIMENTAL
Intervention: Swedish massage therapy (SMT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: light touch (LT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: waitlist control (WLC)
Number of subjects: 66
Study: 27097823

Group type: EXPERIMENTAL
Intervention: Doublebase™ gel (2 fingertip units, twice daily for 4 weeks)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Diprobase® cream (2 fingertip units, twice daily for 4 weeks)
Number of subjects: 37
Study: 23820561

Group type: EXPERIMENTAL
Intervention: Active Recovery (AR; 70% of the power output at lactate threshold)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 10
Study: 22545980

Group type: EXPERIMENTAL
Intervention: Parental monitoring
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Family conflict
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Diabetes self-care
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: A1c levels
Number of subjects: 257
Study: 20805984

Group type: EXPERIMENTAL
Intervention: 10 g dried broccoli sprouts for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ordinary diet (Control)
Number of subjects: 40
Study: 18328050

Group type: EXPERIMENTAL
Intervention: Stainless steel crown (SSC)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Modified open-sandwich restoration
Number of subjects: 87
Study: 16700378

Group type: EXPERIMENTAL
Intervention: External cephalic version
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no external cephalic version attempted)
Number of subjects: 90
Study: 12534405

Group type: EXPERIMENTAL
Intervention: Oral omeprazole
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 12212215

Group type: EXPERIMENTAL
Intervention: Puerarin 400 mg.d-1 for 10 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Regular treatment (inotropic agents, diuretic, vasodilator)
Number of subjects: 78
Study: 8568124

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1868860

Group type: EXPERIMENTAL
Intervention: Insulin treatment (10 units of standard insulin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin-placebo treatment
Number of subjects: 20
Study: 6751183

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (no granulocyte transfusions)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (with recovery of marrow function)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions (with recovery of marrow function)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (without recovery of marrow function)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions (without recovery of marrow function)
Number of subjects: 95
Study: 30909924

Group type: EXPERIMENTAL
Intervention: Long-lasting insecticidal nets (LLINs) distributed to residents along the Padauiri River.
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (Bacabal-rio Aracá and São Sebastião district).
Number of subjects: 208
Study: 29559261

Group type: EXPERIMENTAL
Intervention: Bilateral internal thoracic artery grafting with conversion to other conduit strategies
Number of subjects: 1525

Group type: COMPARATOR
Intervention: Bilateral internal thoracic artery grafting without conversion
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: Bilateral internal thoracic artery grafting with conversion
Number of subjects: 1525
Study: 27825901

Group type: EXPERIMENTAL
Intervention: Kinesthetic training (KinVis) with motor imagery (MI) during dart throwing, 15 training sessions.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group without motor imagery (MI) during dart throwing, 15 training sessions.
Number of subjects: 53
Study: 24924851

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) as add-on to cognitive-behavioral therapy (CBT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 74
Study: 22525912

Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis antigens HSP60, CT376, CT557, and CT443
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: CT875 and CT147
Number of subjects: 73
Study: 20487351

Group type: EXPERIMENTAL
Intervention: Dual-chamber (DC) ICDs with SafeR pacing at 60 bpm
Number of subjects: 450

Group type: COMPARATOR
Intervention: Single-chamber (SC) ICDs with backup pacing at VVI 40 bpm
Number of subjects: 450
Study: 18926460

Group type: EXPERIMENTAL
Intervention: Simulation-based laparoscopic suturing curriculum (TR group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard clinical training (NR group)
Number of subjects: 22
Study: 15886753

Group type: COMPARATOR
Intervention: SST-A octreotide alone (Group A)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: SST-A octreotide with adjuvant treatment (Group B)
Number of subjects: 22
Study: 12585097

Group type: EXPERIMENTAL
Intervention: Cordyceps powder 2‐4 g/d before meal and artemisinin 0.6 g/d after meal for 3 years
Number of subjects: 61

Group type: COMPARATOR
Intervention: Tripterygiitotorum and/or Baoshenkang tablet
Number of subjects: 61
Study: 12534118

Group type: EXPERIMENTAL
Intervention: Fentanyl 3 micrograms kg‐1 during RSI (Group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fentanyl 3 micrograms kg‐1 after intubation (Group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No fentanyl (Control Group C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fentanyl groups (A and B)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study: 9583842

Group type: EXPERIMENTAL
Intervention: B‐group vitamins alone (1 mg folic acid, 7.2 mg pyridoxine, and 0.02 mg cyanocobalamin)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins alone (150 mg ascorbic acid, 67 mg RRR‐alpha‐tocopherol, and 9 mg beta‐carotene)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: B‐group vitamins with antioxidant vitamins
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 8562173

Group type: EXPERIMENTAL
Intervention: FA 200 mg/m2 i.v. plus 5‐FU 400 mg/m2 i.v. on days 1‐5 every 3 weeks
Number of subjects: 185

Group type: COMPARATOR
Intervention: 5‐FU 400 mg/m2 i.v. on days 1‐5 every 4 weeks
Number of subjects: 185
Study: 2766421

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine and Western Medicine (TCM-WM)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Western Medicine (Control)
Number of subjects: 59
Study: 656890

Group type: EXPERIMENTAL
Intervention: 1 g cefuroxime intramuscularly and 1 g probenecid orally
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 1.5 g cefuroxime intramuscularly with 1 g probenecid orally
Number of subjects: 110
Study: 31400480

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) with Hormone Therapy (HT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Hormone Therapy (HT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy Control Group
Number of subjects: 41
Study: 25733749

Group type: EXPERIMENTAL
Intervention: Caregiver-implemented communication intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 97
Study: 23239304

Group type: EXPERIMENTAL
Intervention: 0.025-inch guide wire and sphincterotome group (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.035-inch guide wire and sphincterotome group (n = 50)
Number of subjects: 100
Study: 21348577

Group type: EXPERIMENTAL
Intervention: Visuomotor-imagery therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no supplementary therapy)
Number of subjects: 15
Study: 19850682

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: TTP 150 microg/d
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: TTP 300 microg/d
Number of subjects: 279
Study: 16452585

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 14998677

Group type: EXPERIMENTAL
Intervention: Extracorporeal focused ultrasound surgery (FUS)
Number of subjects: 1038
Study: 11344699

Group type: EXPERIMENTAL
Intervention: famotidine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: cisaprid + famotidine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: cisaprid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: eradication of H.p.
Number of subjects: 40
Study: 9833000

Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 0
Study: 7862833

Group type: EXPERIMENTAL
Intervention: Drink containing 50 g glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Series of glucose-containing drinks raised blood glucose levels for 2 hours
Number of subjects: 0
Study: 3497777

Group type: EXPERIMENTAL
Intervention: 220C Copper T IUD inserted before leaving the delivery room
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no IUD insertion)
Number of subjects: 66
Study: 30529883

Group type: EXPERIMENTAL
Intervention: 20 g/d of high-cocoa chocolate for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no alteration in diet or physical activity)
Number of subjects: 32
Study: 29908991

Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic (300 μg MAGE-A3 antigen plus 420 μg CpG 7909 reconstituted in AS01B, administered via intramuscular injections, up to 13 doses over 27 months)
Number of subjects: 1345

Group type: COMPARATOR
Intervention: Placebo (administered via intramuscular injections, up to 13 doses over 27 months)
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic (in GS-positive population)
Number of subjects: 1345

Group type: COMPARATOR
Intervention: Placebo (in GS-positive population)
Number of subjects: 1345
Study: 27217410

Group type: EXPERIMENTAL
Intervention: Adherent participants (n=16,878)
Number of subjects: 19790

Group type: EXPERIMENTAL
Intervention: Nonadherent participants (n=2912)
Number of subjects: 19790
Study: 25397819

Group type: EXPERIMENTAL
Intervention: Participation in brief 4-week Mindfulness Based Stress Reduction program (n=19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual (TAU, n=21)
Number of subjects: 40
Study: 22673023

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 759

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 759
Study: 19322618

Group type: EXPERIMENTAL
Intervention: Rotating-platform TKA
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fixed-platform TKA
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nonoperated contralateral side
Number of subjects: 54
Study: 18834503

Group type: EXPERIMENTAL
Intervention: Lifetime risk in numerical format (natural frequencies, i.e. X out of 100)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifetime risk in both numerical format and graphical format (population figures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifetime risk and age-related risk in numerical format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifetime risk and age-related risk in both numerical format and graphical format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifetime risk in percentages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (usual care)
Number of subjects: 0
Study: 16491675

Group type: EXPERIMENTAL
Intervention: Anxiogenic condition
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 61
Study: 12957458

Group type: EXPERIMENTAL
Intervention: Irradiation of the internal mammary and medial supraclavicular lymph nodes
Number of subjects: 111

Group type: COMPARATOR
Intervention: No irradiation of the internal mammary and medial supraclavicular lymph nodes
Number of subjects: 111
Study: 11004260

Group type: EXPERIMENTAL
Intervention: Immune recovery uveitis patients undergoing highly active antiretroviral therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Posterior segment complications
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Anterior segment complications
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 21
Study: 8862992

Group type: EXPERIMENTAL
Intervention: Coded postcard intervention
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Control group (three complete anonymous mailings)
Number of subjects: 1600
Study: 1627418

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for 1 year
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 1 year
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 961

Group type: COMPARATOR
Intervention: Irradiation-induced menopause
Number of subjects: 961

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 961